Treatment of aplastic anemias.
D000328:Adult; D000741:Anemia, Aplastic / Q000139:chemically induced / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations / Q000627:therapeutic use; D005198:Fanconi Syndrome / Q000188:drug therapy; D006801:Humans; D007165:Immunosuppression Therapy; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy; D010198:Pancytopenia / Q000139:chemically induced; D010983:Plateletpheresis; D011379:Prognosis; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000961:Antilymphocyte Serum; D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole